Back Hepatitis C

Hepatitis C

AASLD 2017: Nivolumab Improves Outcomes in Liver Cancer Study

Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumor size or disease stabilization in patients with hepatocellular carcinoma (HCC) in the CheckMate 040 study, according to a report at the 2017 AASLD Liver Meeting last month in Washington, DC.

alt

AASLD 2017: More Work and Lower Drug Prices Needed to Eliminate Hepatitis C Worldwide

Eliminating hepatitis C virus (HCV) as a global public health concern is feasible, but to do so more people need to be tested and treated, and prices of direct-acting antivirals need to come down, according to presentations at the AASLD Liver Meeting last month in Washington, DC.

alt

AASLD 2017: Curing Hepatitis C Leads to Improved Quality of Life

People who were cured of hepatitis C with direct-acting antivirals had sustained improvements in their health-related quality of life, including both physical and mental health measures, according to study results presented at the AASLD Liver Meeting last week in Washington, DC.

alt

AASLD 2017: Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV

An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to sustained response in all HIV-positive with genotype 1 or 4 acute hepatitis C virus (HCV) infection in the SWIFT-C study, according to a reportat the AASLD Liver Meeting last month in Washington, DC.

alt

AASLD 2017: Mavyret Shows High Cure Rates for HCV Genotype 3 and Cirrhosis

Glecaprevir and pibrentasvir, the 2 drugs in the recently approved Mavyret coformulation, demonstrated high sustained response rates for chronic hepatitis C patients with HCV genotype 3 and for people with liver cirrhosis, according to a pair of reports presented at the 2017 AASLD Liver Meeting last week in Washington, DC.

alt

AASLD 2017: Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV

An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to sustained response in all HIV-positive with genotype 1 or 4 acute hepatitis C virus (HCV) infection in the SWIFT-C study, according to a reportat the AASLD Liver Meeting last month in Washington, DC.

alt

AASLD 2017: Curing Hepatitis C with DAAs Reduces Liver Cancer Risk

People who achieved a sustained virological response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, according to study results presented at the 2017 AASLD Liver Meeting last week in Washington, DC.

alt

 

Coverage of the 2017 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2017 Liver Meeting, the annual conference of the American Association for the Study of Liver Diseases, AASLD), October 20-24, 2017, in Washington, DC.

alt

AASLD 2017: HCV Infections Are Rising Among HIV+ Gay Men In San Diego

Hepatitis C incidence is increasing among gay and bisexual men living with HIV in San Diego, according to the largest analysis of its kind done in the United States. Study results were presented last week at the 2017 AASLD Liver Meeting in Washington, DC.

alt